Abstract
Patients who receive hematopoietic stem cell transplantation (HSCT) are usually administered a calcineurin inhibitor. Because vancomycin is associated with an increased incidence of nephrotoxicity, neutropenic patients receiving HSCT are considered a high-risk population for nephrotoxicity with vancomycin. We retrospectively compared the efficacy and safety of vancomycin and teicoplanin in febrile neutropenic patients receiving HSCT. A single-centre, retrospective cohort study was conducted at the 614-bed Gifu University Hospital in Japan. Patients who received HSCT and were administered vancomycin or teicoplanin by injection for febrile neutropenia from 1 January 2012 to 31 August 2017 were enrolled. Time to attain an effective trough concentration, clinical efficacy and adverse events were compared between the two groups. Time to attain an effective trough concentration of over 10 μg/mL tended to be shorter in the teicoplanin group than in the vancomycin group (median 3, 95% confidence interval [CI] 2.4-3.6 days vs median 6, 95% CI 1.5-10.5 days; hazard ratio [HR] 0.4, 95% CI 0.15-1.06; P = .066). The rate of clinical failure was lower in the teicoplanin group than in the vancomycin group (18.8% vs 53.8%, P = .113). In additi...Continue Reading
References
Jan 1, 1993·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A MicozziP Martino
Feb 1, 1996·The Journal of Antimicrobial Chemotherapy·M J Wood
Jun 6, 2000·The Journal of Antimicrobial Chemotherapy·I HardingV Reed
Apr 26, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hilmar WisplinghoffMichael B Edmond
Apr 17, 2004·Clinical Pharmacokinetics·Federico PeaMario Furlanut
Feb 11, 2005·Chemical Reviews·Dan KahneChristopher Walsh
Nov 30, 2005·Transplantation·Thomas FehrMegan Sykes
Jan 18, 2006·Biochemical Pharmacology·John L Pace, Guang Yang
Oct 12, 2007·The New England Journal of Medicine·Frederick R Appelbaum
Jan 15, 2008·Infection·C Hahn-AstM Von Lilienfeld-Toal
Jun 10, 2008·American Journal of Infection Control·Teresa C HoranMargaret A Dudeck
Jul 15, 2009·Antimicrobial Agents and Chemotherapy·Shuli SvetitskyMical Paul
Sep 14, 2010·Journal of Clinical Pharmacy and Therapeutics·Y HirakiY Tsuji
Jan 6, 2011·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·UNKNOWN Japanese Society of ChemotherapyKohya Shiba
Nov 9, 2011·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Takashi UedaMotoi Uchino
Jun 11, 2014·Blood·Shernan G HoltanDaniel J Weisdorf
Sep 30, 2016·Therapeutic Drug Monitoring·Keita HiraiKunihiko Itoh
Oct 5, 2016·Annals of Hematology·Heidrun BoztugMichael Dworzak
Jun 25, 2017·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Shinichi WatanabeTakuro Kanekura
Nov 24, 2017·Chemotherapy·Yuhki SatoHiroki Itoh
May 13, 2018·International Urology and Nephrology·Xiao-Yu ChenXue-Feng Xie
Aug 30, 2018·Therapeutic Drug Monitoring·Hidetoshi IshiiKunihiko Itoh
Dec 1, 2018·Infection·Oguz Resat SipahiSercan Ulusoy
Jan 12, 2019·Expert Review of Hematology·Vanessa E Kennedy, Lori S Muffly
Citations
Jul 14, 2020·Journal of Clinical Pharmacy and Therapeutics·Koichi OhataAkio Suzuki
Nov 20, 2020·Infection and Drug Resistance·Dan SunYalin Dong
Jan 7, 2021·Antibiotics·Jian PengEleftherios Mylonakis
May 14, 2021·BMC Infectious Diseases·Ching-Yen TsaiI-Ling Chen
Jul 2, 2021·Curēus·Jasmeet KaurRafiullah Khan
Oct 30, 2021·Basic & Clinical Pharmacology & Toxicology·Toshinori HiraiTakuya Iwamoto